Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended ...

Rigel Pharmaceuticals (RIGL) stock hits a 4-month low as 2026 revenue guidance signals a topline contract due to falling contract revenue. Read more here.

Rigel Pharmaceuticals is back in focus as analysts update their narrative around the stock, with the fair value price target holding steady at $51.6. Supportive voices point to this unchanged figure ...

Rigel Pharmaceuticals (NASDAQ:RIGL) detailed record commercial performance for the fourth quarter and full year 2025, while outlining plans to pursue additional in-licensing opportunities and advance ...

SOUTH SAN FRANCISCO, Calif., June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL), Inc. today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the 2023 ...

Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.

Return on Assets (ROA): Rigel Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 12.42%, the company showcases ...

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were $40 ...